Sertraline in the Prevention of Depression
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A group of 480 patients, aged 19–78 with an HRSD score of at least 17 and who met DSM–III criteria for major depressive disorder were studied. Patients were given placebo for a one-week single-blind run-in period, after which sertraline was administered for eight weeks. This was followed by 44 weeks in which patients received sertraline or placebo on a double-blind, randomised basis. Patients were assessed periodically using the 17-item HRSD and the Clinical Global Impression scales. During the entire double-blind period 24 (13.0%) sertraline patients relapsed compared with 48 (45.7%) placebo patients (P<0.001). The protective effect of sertraline was maintained throughout the 44 weeks. The study provides evidence that sertraline prevents relapse of the index episode of depression as well as recurrence of further episodes and has few side-effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prien, R. F. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790220086014 · Cited by 565
Research works printed but not linked: 14
- Guy, 1976, ECDEU Assessment Manual for Psychopharmacology
- Coppen, 1986, Pharmacotherapy of Depressive Disorders: A Consensus Statement
- 10.1111/j.1600-0447.1988.tb06301.x · DOI · Paper page
- 10.1136/bmj.289.6451.1052 · doi:10.1136/bmj.289.6451.1052
- Reimherr, 1988, Sertraline, a selective inhibitor of serotonin uptake, for the treatment of outpatients with major depressive disorder, Psychopharmacology Bulletin, 24, 200
- Montgomery, 1988, The prophylactic efficacy of fluoxetine in unipolar depression, British Journal of Psychiatry, 153, 69, 10.1192/S0007125000297328 · DOI · Paper page
- 10.1111/j.1600-0447.1983.tb11122.x · DOI · Paper page
- 1980, Diagnostic and Statistical Manual of Mental Disorders
- 10.1136/jnnp.23.1.56 · DOI · Paper page
- Doogan, 1988, Sertraline: a new antidepressant, Journal of Clinical Psychiatry, 49, 46
- Lehmann, 1975, Non-Parametrics: Statistical Methods Based on Ranks
- Koe, 1983, Sertraline, 1S,4S-N-methyl-4(3,4-dichlorophenyl)-1,2,3,4-tetrahydro 1-naphthylamine, a new uptake inhibitor with selectivity for serotonin, Journal of Pharmacology and Experimental Therapeutics, 226, 686, 10.1016/S0022-3565(25)21773-6 · DOI · Paper page
- 10.1080/01621459.1958.10501452 · DOI · Paper page
- 10.1001/archpsyc.1979.01780080023006 · DOI · Paper page
Cited by
Sertraline treatment of major depression in patients with acute MI or unstable angina
Glassman, A. H. (2002) · JAMA · doi:10.1001/jama.288.6.701 · Cited by 1,414
Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945
Rush, A. J., George, M. S., Sackeim, H. A., Marangell, L. B., Husain, M. M., Giller, C., Nahas, Z., Haines, S., Simpson, R. K., & Goodman, R. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00304-2 · Cited by 688
Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication.
Kirsch, I., & Sapirstein, G. (1998) · Prevention & Treatment · doi:10.1037/1522-3736.1.1.12a · Cited by 502
Tianeptine: A Review of its Use in Depressive Disorders
Wagstaff, A. J., Ormrod, D., & Spencer, C. M. (2001) · CNS Drugs · doi:10.2165/00023210-200115030-00006 · Cited by 394
Keller, M. B. (2003) · JAMA · doi:10.1001/jama.289.23.3152 · Cited by 388
Preskorn, S. H. (1997) · Clinical Pharmacokinetics · doi:10.2165/00003088-199700321-00003 · Cited by 370
Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression
Mace, S., & Taylor, D. (2000) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.1.5.917 · Cited by 315
Effect of sertraline on regional metabolic rate in patients with affective disorder
Buchsbaum, M. S., Joseph, W., Siegel, B. V., Hackett, E., Trenary, M., Abel, L., & Reynolds, C. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00097-2 · Cited by 303
Keller, M. B., & Boland, R. J. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00110-3 · Cited by 281
Ketamine as a Prophylactic Against Stress-Induced Depressive-like Behavior
Brachman, R. A., McGowan, J. C., Perusini, J. N., Lim, S. C., Pham, T. H., Faye, C., Gardier, A. M., Mendez-David, I., David, D. J., Hen, R., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.04.022 · Cited by 257
Sim, K., Lau, W. K., Sim, J., Sum, M. Y., & Baldessarini, R. J. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv076 · Cited by 218
“…1989 Imipramine 54 1.69 (1.10–2.60) 3.0 (1.7–11) 1.75 Quitkin et al., 1989 Phenelzine 53 1.93 (1.19–3.12) 2.6 (1.6–6.6) 1.59 Rouillon et al., 1989 Maprotiline 1 141 1.44 (1.13–1.84) 14 (8.2–45) 2.38 Doogan and Caillard, 1992 Sertraline 295 3.50 (2.29–5.36) 3.1 (2.3–4.5) 1.77 Montgomery et al.,…”
InfluentialFluoxetine versus placebo in preventing relapse of major depression in children and adolescents
Emslie, G. J., Kennard, B. D., Mayes, T. L., Nightingale-Teresi, J., Carmody, T., Hughes, C. W., Rush, A. J., Tao, R., & Rintelmann, J. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07091453 · Cited by 188
Hansen, R., Gaynes, B., Thieda, P., Gartlehner, G., Deveaugh-Geiss, A., Krebs, E., & Lohr, K. (2008) · Psychiatric Services · doi:10.1176/ps.2008.59.10.1121 · Cited by 172
Goldstein, B. J., & Goodnick, P. J. (1998) · Journal of Psychopharmacology · doi:10.1177/0269881198012003041 · Cited by 171
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Discontinuing antidepressant treatment in major depression.
Viguera, A. C., Baldessarini, R. J., & Friedberg, J. (1998) · Harvard Review of Psychiatry · doi:10.3109/10673229809003578 · Cited by 145
Kaymaz, N., van Os, J., Loonen, A. J. M., & Nolan, W. A. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0910 · Cited by 135
Kishi, T., Ikuta, T., Sakuma, K., Okuya, M., Hatano, M., Matsuda, Y., & Iwata, N. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01824-z · Cited by 136
Predictors of Relapse in a Prospective Study of Fluoxetine Treatment of Major Depression
McGrath, P. J., Stewart, J. W., Quitkin, F. M., Chen, Y., Alpert, J. E., Nierenberg, A. A., Fava, M., Cheng, J., & Petkova, E. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1542 · Cited by 111
Andrews, P. W., Kornstein, S. G., Halberstadt, L. J., Gardner, C. O., & Neale, M. C. (2011) · Frontiers in Psychology · doi:10.3389/fpsyg.2011.00159 · Cited by 107
Braun, C., Bschor, T., Franklin, J., & Baethge, C. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000442293 · Cited by 103
Meta-analysis of relapse prevention antidepressant trials in depressive disorders
Glue, P., Donovan, M. R., Kolluri, S., & Emir, B. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048671003705441 · Cited by 100
Van Leeuwen, E., van Driel, M. L., Horowitz, M. A., Kendrick, T., Donald, M., De Sutter, A. I., Robertson, L., & Christiaens, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013495.pub2 · Cited by 90
Preventing Relapse and Recurrence of Depression:A Brief Review of Therapeutic Options
Thase, M. E. (2006) · CNS Spectrums · doi:10.1017/s1092852900015212 · Cited by 93
Clevenger, S. S., Malhotra, D., Dang, J., Vanle, B., & IsHak, W. W. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317737264 · Cited by 83
Lépine, J.-P., Caillard, V., Bisserbe, J.-C., Troy, S., Hotton, J.-M., Boyer, P., & For the PREVERS Investigators (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.836 · Cited by 83
Self-citationGelenberg, A. J., Trivedi, M. H., Rush, A. J., Thase, M. E., Howland, R., Klein, D. N., Kornstein, S. G., Dunner, D. L., Markowitz, J. C., Hirschfeld, R. M. A., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01971-6 · Cited by 76
Wilson, K. C. M., Mottram, P. G., Ashworth, L., & Abou-Saleh, M. T. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.6.492 · Cited by 74
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.004 · Cited by 69
Weihs, K. L., Houser, T. L., Batey, S. R., Ascher, J. A., Bolden-Watson, C., Donahue, R. M. J., & Metz, A. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01317-8 · Cited by 65
Nierenberg, A. A., Quitkin, F. M., Kremer, C., Keller, M. B., & Thase, M. E. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300405 · Cited by 51
“This is not an insignificant problem since recurrence rates vary from 15 to 40% in long-term clinical trials, a proportion mirrored in clinical practice (Coppen et al, 1978; Prien et al, 1973, 1984; Montgomery et al, 1988; Rouillon et al, 1989; Frank et al, 1990; Doogan and Caillard, 1992; Kupfer et al, 1992; Montgome…”
BackgroundStudies of Long-Term Use of Antidepressants: How Should the Data from Them be Interpreted?
El-Mallakh, R. S., & Briscoe, B. (2012) · CNS Drugs · doi:10.2165/11599450-000000000-00000 · Cited by 36
(2014) · Europe PMC (PubMed Central) · Cited by 24
Franchini, L., Rossini, D., Bongiorno, F., Spagnolo, C., Smeraldi, E., & Zanardi, R. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00188-8 · Cited by 20
Metadata
- Authors
- Doogan, D. P., & Caillard, V.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 1992-02
- Volume
- 160
- Issue
- 2
- Pages
- 217-222
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2055052693
- Cited by
- 245
- References
- 1
- FWCI
- 17.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.